#USA #Seattle #Artivion #AATS #NEXUS TRIOMPHE

Artivion Presents New Insights at AATS Annual Gathering

Artivion, Inc. has made waves in the medical community following its presentation of crucial clinical data from the NEXUS TRIOMPHE trial during the 105th Annual Meeting of the American Association for Thoracic Surgery (AATS) in Seattle, Washington. The focus of this presentation was a novel approach to treating chronic aortic dissection, with results derived from a specific cohort of 54 patients classified as high-risk for traditional surgical interventions.

Overview of the Presentation

The presentation, led by Dr. Bradley Leshnower, a prominent figure in thoracic aortic surgery at Emory University, detailed the 30-day outcomes of patients who underwent treatment using the NEXUS device—a unique, single-branch arch stent graft designed for minimal invasiveness. Dr. Leshnower's findings illustrated a 63% reduction in the major adverse event (MAE) rate in patients treated with this innovative approach compared to the standard performance goals previously established by the FDA.

In technical terms, the study reported a significant improvement in both clinical outcomes and device performance, leading to an impressive drop in major complications such as mortality, stroke, and renal failure. Specifically, the study noted a MAE occurrence of only 13% in patients treated with the NEXUS device, compared to a staggering 35% in the reference benchmarks, with p-values indicating strong statistical significance (p <0.001).

Implications for Patients and Surgeons

Dr. Leshnower emphasized the importance of this technology, remarking that it opens doors for patients who previously may have faced barriers to treatment due to the high risks associated with open surgical repair of aortic arch aneurysms. He pointed out, "The 30-day results from the TRIOMPHE study demonstrate that aneurysms due to chronic aortic arch dissection can be effectively managed with this new off-the-shelf stent graft system."

Artivion's CEO, Pat Mackin, expressed optimism about the trial results, indicating that these findings are likely to encourage more inclusive treatment options for patients suffering from aortic arch diseases. This aligns perfectly with Artivion's mission to provide innovative solutions to complex cardiac challenges.

The NEXUS TRIOMPHE Clinical Trial

The NEXUS TRIOMPHE trial is pivotal in the U.S., focusing on assessing the effectiveness of the NEXUS device for endovascular treatment of chronic aortic dissection. This trial not only evaluates new medical techniques but also aims to establish safer treatment alternatives for high-risk patients.

The trial's clinical module is expected to culminate with the filing of a premarket approval (PMA) application after a year of rigorous follow-up with the participating patients. Given the current momentum sparked by these preliminary results, the medical community is keenly awaiting further updates from this trial.

About Artivion, Inc.

Headquartered in Georgia, Artivion has carved out a reputation as a frontrunner in cardiac and vascular surgery innovations. The company focuses on developing a range of medical devices, including aortic stent grafts and On-X mechanical heart valves, which cater to some of the most critical challenges in treating aortic disease. With a global market presence in over 100 countries, Artivion continues to expand its impact in cardiac medicine.

For those interested in learning more about Artivion and its groundbreaking work, details are available on their official website at www.Artivion.com.

As the AATS conference wraps up, the excitement around these findings reiterates the importance of continuous innovation in medical treatments, especially for conditions as severe as those affecting the aorta. The medical community looks forward to the implications these results will have on future surgical practices and patient care.